Molecular Level Insight Into the Benefit of Myricetin and Dihydromyricetin Uptake in Patients With Alzheimer's Diseases

• Published in: Frontiers in aging neuroscience Vol. 12; p. 601603
• Main Authors: Liu, Miaomiao, Guo, Hong, Li, Zhongyuan, Zhang, Chenghua, Zhang, Xiaoping, Cui, Qinghua, Tian, Jingzhen
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Research Foundation 23.10.2020; Frontiers Media S.A
• Subjects: Alzheimer's disease; Amyloid; Autophagy; Binding sites; Dietary supplements; Dihydromyricetin; Disease; Inflammation; mechanism of action; Metal ions; Myricetin; natural product; Natural products; Neurodegenerative diseases; Neuroscience; Oxidative stress; Pathogenesis; Peptides; Phagocytosis; United States > US; Dihydromyricetin; mechanism of action; Alzheimer’s disease; Myricetin; natural product
• ISSN: 1663-4365; 1663-4365
• DOI: 10.3389/fnagi.2020.601603

Alzheimer's disease (AD) is a neurodegenerative disease with a high incidence rate and complicated pathogenesis. Currently, all anti-AD drugs treat the symptoms of the disease, and with currently no cure for AD. Flavonoid containing natural products, Myricetin (MYR) and Dihydromyricetin (DMY), are abundant in fruits and vegetables, and have been approved as food supplements in some countries. Interestingly, MYR and DMY have been reported to have anti-AD effects. However, the underlying anti-AD mechanism of action of MYR and DMY is complex with many facets being identified. In this review, we explore the benefit of MYR and DMY in AD patients from a molecular level. Their mechanism of action are discussed from various aspects including amyloid β-protein (Aβ) imbalance, neuroinflammation, dyshomeostasis of metal ions, autophagy disorder, and oxidative stress.